WO2014094386A1 - 一种干细胞培养基及其应用和干细胞培养方法 - Google Patents
一种干细胞培养基及其应用和干细胞培养方法 Download PDFInfo
- Publication number
- WO2014094386A1 WO2014094386A1 PCT/CN2013/071173 CN2013071173W WO2014094386A1 WO 2014094386 A1 WO2014094386 A1 WO 2014094386A1 CN 2013071173 W CN2013071173 W CN 2013071173W WO 2014094386 A1 WO2014094386 A1 WO 2014094386A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- stem cell
- cell culture
- culture medium
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 174
- 239000006143 cell culture medium Substances 0.000 title claims abstract description 62
- 238000004113 cell culture Methods 0.000 title abstract description 8
- 210000001519 tissue Anatomy 0.000 claims abstract description 21
- 150000002632 lipids Chemical class 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 102000004127 Cytokines Human genes 0.000 claims abstract description 9
- 108090000695 Cytokines Proteins 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 229940088594 vitamin Drugs 0.000 claims abstract description 8
- 229930003231 vitamin Natural products 0.000 claims abstract description 8
- 235000013343 vitamin Nutrition 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 13
- 210000000056 organ Anatomy 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 11
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 229960002429 proline Drugs 0.000 claims description 11
- 235000019163 vitamin B12 Nutrition 0.000 claims description 11
- 239000011715 vitamin B12 Substances 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 10
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 10
- 102100035194 Placenta growth factor Human genes 0.000 claims description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 10
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 10
- 229960003957 dexamethasone Drugs 0.000 claims description 10
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims description 10
- 210000003954 umbilical cord Anatomy 0.000 claims description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 9
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 9
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 239000005642 Oleic acid Substances 0.000 claims description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 229960001031 glucose Drugs 0.000 claims description 9
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 229960000367 inositol Drugs 0.000 claims description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 9
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 9
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 235000019192 riboflavin Nutrition 0.000 claims description 9
- 239000002151 riboflavin Substances 0.000 claims description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 235000019743 Choline chloride Nutrition 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- 102000004338 Transferrin Human genes 0.000 claims description 8
- 108090000901 Transferrin Proteins 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 229960003767 alanine Drugs 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 229960003121 arginine Drugs 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 235000009697 arginine Nutrition 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- XXWCODXIQWIHQN-UHFFFAOYSA-N butane-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NCCCCN XXWCODXIQWIHQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 235000011148 calcium chloride Nutrition 0.000 claims description 8
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 8
- 229960003178 choline chloride Drugs 0.000 claims description 8
- 229960002433 cysteine Drugs 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 229960002449 glycine Drugs 0.000 claims description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 8
- 235000019136 lipoic acid Nutrition 0.000 claims description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 8
- 235000011147 magnesium chloride Nutrition 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- 229960005190 phenylalanine Drugs 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- 210000001525 retina Anatomy 0.000 claims description 8
- 229960001153 serine Drugs 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229940054269 sodium pyruvate Drugs 0.000 claims description 8
- 229960002663 thioctic acid Drugs 0.000 claims description 8
- 229960002898 threonine Drugs 0.000 claims description 8
- 239000012581 transferrin Substances 0.000 claims description 8
- 229960004441 tyrosine Drugs 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- 229960001008 heparin sodium Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 6
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims description 6
- 229960002743 glutamine Drugs 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- 229960003646 lysine Drugs 0.000 claims description 6
- 229960004452 methionine Drugs 0.000 claims description 6
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 6
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 6
- 229960004799 tryptophan Drugs 0.000 claims description 6
- 102100037362 Fibronectin Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 5
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 5
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 210000005013 brain tissue Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 108010085895 Laminin Proteins 0.000 claims description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- -1 stem cell factor Proteins 0.000 claims description 3
- 101710186630 Insulin-1 Proteins 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 229940068459 sodium pantothenate Drugs 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 102000002356 Nectin Human genes 0.000 claims 1
- 108060005251 Nectin Proteins 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- NGBBFNQEPSYETA-UHFFFAOYSA-N octadecanoic acid;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(O)=O NGBBFNQEPSYETA-UHFFFAOYSA-N 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 37
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 9
- 210000004700 fetal blood Anatomy 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 58
- 230000004069 differentiation Effects 0.000 description 15
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 12
- 210000001612 chondrocyte Anatomy 0.000 description 11
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002207 retinal effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000002293 adipogenic effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 210000000608 photoreceptor cell Anatomy 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003757 neuroblast Anatomy 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N pantothenic acid Chemical compound OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229940049906 glutamate Drugs 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FZUJWWOKDIGOKH-UHFFFAOYSA-N sulfuric acid hydrochloride Chemical compound Cl.OS(O)(=O)=O FZUJWWOKDIGOKH-UHFFFAOYSA-N 0.000 description 2
- CYTCTRAEJYIZRX-UHFFFAOYSA-N (9a-hydroxy-3,5a-dimethyl-9-methylidene-2-oxo-3,3a,4,5,6,7,8,9b-octahydrobenzo[g][1]benzofuran-6-yl) acetate Chemical compound C1CC2(C)C(OC(C)=O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CYTCTRAEJYIZRX-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- JJACPQWGBIQRJD-UHFFFAOYSA-N C(C(C)C)N1C(N(C(C=2NC=NC12)=O)C1C=CC2=CC=CC=C12)=O Chemical compound C(C(C)C)N1C(N(C(C=2NC=NC12)=O)C1C=CC2=CC=CC=C12)=O JJACPQWGBIQRJD-UHFFFAOYSA-N 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- QGAVSDVURUSLQK-UHFFFAOYSA-N ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
Definitions
- the present invention relates to the field of cell culture, and more particularly to a stem cell culture medium and application thereof and a dry and fine culture method. Background technique
- stem cells can not only self-renew, but also differentiate into other functional cells under appropriate conditions. Therefore, stem cells are expected to be effective means for treating difficult diseases in humans. However, stem cells are abundant in normal adult tissues. How to rapidly expand and culture stem cells in vitro is an important technique for studying the mechanism of stem cells and exploring their therapeutic methods for treating human diseases.
- Stem cells are as small as possible, but are widely distributed in various tissues and organs of mammals, including but not limited to bone marrow, umbilical cord, adipose tissue, brain tissue, retina, heart, liver, lung, and skin. Numerous studies have shown that these low-level stem cells can be further expanded in vitro by an appropriate method.
- the most common medium for culturing stem cells is a medium supplemented with fetal bovine serum.
- stem cells cultured in this medium not only grow slowly, but also have a much lower potential for differentiation into functional cells after more than 5 passages.
- the potential non-repetition of bovine serum batches also greatly affects their scale.
- bovine serum is heterogeneous to humans, thus limiting its clinical application. Therefore, explore the rapid expansion of stem cells without affecting The optimal combination of its potential culture conditions and its media composition is a very important research content. Summary of the invention
- the present invention aims to provide a stem cell culture medium and application thereof and a stem cell culture method, aiming at solving the problem that the growth of stem cells in the medium supplemented with the existing bovine serum is slow and the cell potential is passaged. The problem of greatly decreasing the number of times.
- a stem cell culture medium wherein the stem cell culture medium contains no serum, and the stem cell culture medium comprises amino acids, vitamins, salts, lipids, cytokines and protein polypeptides;
- amino acid comprises alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine , methionine, phenylalanine, valine, serine, threonine, tryptophan, tyrosine, proline and glutamine;
- the cytokine and protein polypeptides include fibroblast growth factor 1, fibroblast growth factor 2, epidermal growth factor, platelet-derived growth factor, insulin, insulin-like growth factor 1, vascular endothelial growth factor, placental growth factor, leukemia Inhibitory factor, stem cell factor, transferrin and human serum albumin;
- the vitamins include biotin, choline chloride, D-calcium pantothenate, folic acid, inositol, nicotinamide, pyridoxine hydrochloride, riboflavin, sulphate hydrochloride, coenzyme Q10, vitamin B12, Putrescine dihydrochloride, vitamin C and vitamin E;
- the lipids include dexamethasone, oleic acid, cholesterol, ethanolamine, linoleic acid, lipoic acid, and a mixture of lipids;
- the salts include sodium hydrogencarbonate, calcium chloride, potassium chloride, magnesium chloride, magnesium sulfate, sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate and sodium pyruvate;
- the stem cell culture medium also includes an antioxidant, D-glucose, taurine, and sodium heparin.
- the stem cell culture medium wherein the stem cell culture medium is calculated in 1 liter, and comprises the following components:
- stem cell culture medium as described above, wherein the stem cell medium is used for culturing a thousand cells.
- stem cells include, but are not limited to, stem cells of human and mammalian origin.
- the stem cell culture medium wherein the stem cells are isolated from various tissues or organs; the tissues and organs include, but are not limited to, bone marrow, umbilical cord, adipose tissue, brain tissue, retina, heart, liver, Lungs and skin.
- the method for culturing stem cells wherein the material for promoting adherence of stem cells is one or more of collagen, gelatin, polylysine, fibronectin, laminin, and fibronectin. mixture.
- the stem cell culture medium provided by the present invention which is serum-free, is suitable for rapidly culturing stem cells derived from human and mammalian tissues, including but not limited to adipose-derived mesenchymal stem cells, bone marrow mesenchymal stem cells, and cord blood stem cells.
- This medium increases the rate of cell expansion by a factor of 3-5, but does not affect its potential for differentiation.
- the stem cell culture medium can not only rapidly expand stem cells from different sources, prolong the number of passages, but also maintain the potential of stem cells.
- Figure la is a schematic diagram showing the results of detection of the expansion rate of stem cells in the culture medium of the present invention using the stem cell culture medium of the present invention and the conventional culture medium.
- Figure 1b is a schematic diagram showing the results of detecting the expansion rate of stem cells of BMSCs cultured in the stem cell culture medium of the present invention and the conventional culture medium in Example 1.
- Figure lc is a schematic diagram showing the results of detection of the expansion rate of stem cells in UMBSC cultured in the stem cell culture medium of the present invention and the conventional culture medium in Example 1.
- FIG. 2 is a schematic diagram showing the detection results of in vitro differentiation of chondrocytes by ADSC, BMSC and UMBSC cultured in the stem cell culture medium and the conventional medium according to the present invention.
- 3 is a schematic diagram showing the detection results of differentiation of ADSCs, BMSCs, and UMBSCs into adipocytes in vitro by the stem cell culture medium of the present invention and the conventional medium in Example 3.
- Fig. 4 is a schematic diagram showing the results of in vitro differentiation of ADSC, BMSC and UMBSC cultured in the stem cell culture medium of the present invention and the conventional medium in the present invention.
- Fig. 5 is a view showing the results of detecting the potential of ADSC, BMSC and UMBSC cultured into the retinal epithelial cells in vitro by the stem cell culture medium of the present invention and the conventional medium in Example 5.
- Fig. 6 is a view showing the results of detecting the protective effect of ADSC, BMSC and UMBSC cultured in the stem cell culture medium of the present invention on the photoreceptor degenerative retinal model in Example 6 of the present invention. detailed description
- the present invention provides a stem cell culture medium, an application thereof, and a stem cell culture method.
- a stem cell culture medium an application thereof, and a stem cell culture method.
- the stem cell culture medium provided by the present invention contains no serum, and the formulation relates to the addition of amino acids, vitamins, salts, lipids, cytokines and protein polypeptides, and the cell culture method involves promoting the use of cell adherent materials. Compared with common medium, this method not only can rapidly expand stem cells from different sources, prolongs the number of passages, but also maintains well. The potential of stem cells.
- the stem cell culture medium is suitable for rapid cultivation of stem cells derived from human and mammalian tissues, including but not limited to adipose-derived mesenchymal stem cells, bone marrow mesenchymal stem cells, and cord blood stem cells.
- the stem cell culture medium includes amino acids, vitamins, salts, lipids, cytokines, and protein polypeptides;
- amino acid comprises alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine , methionine, phenylalanine, valine, serine, threonine, tryptophan, tyrosine, proline and glutamine;
- the cytokine and protein polypeptides include fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin (insulin), insulin-like Growth factor 1 ( IGF1 ), vascular endothelial growth factor (VEGF ), placental growth factor ( PGF ), leukemia inhibitory factor ( LIF ), stem cell factor ( SCF ), transferrin and human serum albumin (HSA ) ;
- FGF1 fibroblast growth factor 1
- FGF2 fibroblast growth factor 2
- EGF epidermal growth factor
- PDGF platelet-derived growth factor
- IGF1 insulin-like Growth factor 1
- VEGF vascular endothelial growth factor
- PGF leukemia inhibitory factor
- SCF stem cell factor
- HSA human serum albumin
- the vitamins include biotin, choline chloride, D-pantothenate, folic acid, inositol, nicotinamide, pyridoxine hydrochloride, riboflavin, sulphate hydrochloride, coenzyme Q10, vitamin B12, putrescine II Hydrochloride, vitamin C and vitamin E;
- the lipids include dexamethasone, oleic acid, cholesterol, ethanolamine, linoleic acid, lipoic acid, and a lipid mixture (Sigma, L5416);
- the trace elements include green cobalt, sodium selenite, nickel chloride, manganese chloride, sodium edetate, ammonium heptamolybdate, aluminum chloride, potassium sulphate, copper sulphate, iron nitrate, sulfuric acid Ferrous or zinc sulphate;
- antioxidants ⁇ -mercaptoethanol, reduced glutathione
- the stem cell culture medium is calculated in 1 liter and includes the following components:
- Coenzyme Q10 (Coenzyme Q10) 0.2 ⁇ 5 ⁇
- Vitamin B12 (Vitamin B12) 0.1 ⁇ 2.5 ⁇
- Putrescine dihydrochloride (Putresicine.2HCI) 0.1 ⁇ 2.5 ⁇
- Vitamin C (Vitamin C) 2 ⁇ 50 mg/L
- Vitamin E (Vitamin E) 0.05-1.25 mg/L
- Phenol red 1.62-40.5 mg/L
- Linoleic acid 0.5-7.5 mg/L
- Lipid mixture (Sigma, L5416) 0.2-5 ml/L
- Disodium hydrogen phosphate Na 2 HP0 4 0.1-2.5 mM
- the medium provided by the present invention is suitable for rapid cultivation of stem cells derived from human and mammalian tissues, including but not limited to adipose-derived mesenchymal stem cells, bone marrow mesenchymal stem cells, and cord blood stem cells.
- This medium can increase the rate of cell expansion by 3-5 times without affecting its potential for differentiation.
- the stem cells cultured in the medium provided by the present invention can differentiate into functional cells like the stem cells cultured in the conventional medium, and the functional cells thereof include, but are not limited to, fat cells, chondrocytes, nerve cells, and retinal pigment epithelium. Cells, photoreceptor cells of the retina.
- the stem cells cultured in the medium described in the present invention like stem cells cultured in a conventional medium, have a good protective effect on degenerative tissues or organs after cell transplantation; on the other hand, as described in the present invention
- the stem cells cultured in the medium can be restored to the original function after being transplanted like the stem cells cultured in the conventional medium.
- the stem cell culture medium is used for culturing stem cells, including but not limited to stem cells derived from humans and mammals (such as mice, rats, rabbits).
- stem cells can be isolated from various tissues or organs. Tissues and organs include, but are not limited to, bone marrow, umbilical cord, adipose tissue, brain tissue, retina, heart, liver, lung, and skin.
- the culture medium of the present invention does not contain a substance capable of adhering the stem cells to the adherence, it is necessary to use a stem cell adhering material such as collagen or gelatin before culturing the stem cells. , one or more mixtures of polylysine, fibronectin, laminin, and fibronectin.
- the serum-containing medium contains these things, it is not necessary to add; whereas the stem cell culture medium without serum of the present invention does not contain these things, so it is necessary to coat the adherent material with jni before culturing the stem cells, and then The stem cell culture medium and stem cells of the present invention are sequentially added, and then the stem cells are cultured according to a conventional culture method.
- the stem cell culture medium used is calculated in 1 liter and includes the following components: Concentration or amount
- Trp tryptophan 0.10 mM
- GEF Epidermal Growth Factor
- FGF1 Fibroblast growth factor 1
- FGF2 Fibroblast growth factor 2
- IGF1 Insulin-like Growth factor 1
- LIF Leukocyte factor
- PDGF Platelet-derived growth factor
- PPF Placental growth factor
- SCF Stem cell factor
- VEGF Vascular Endothelial Growth Factor 1-10 ⁇ Insulin 5 mg/L transferrin 20 mg/L Human serum albumin (HSA) 0.1 g/ L biotin 30 ⁇ Choline chloride 60 ⁇ Folic acid 6 ⁇ Coenzyme Q10 1 ⁇ Dexamethasone 10 ⁇
- Vitamin B12 (Vitamin B12) 0.5 ⁇
- Putrescine dihydrochloride (Putresicine.2HCI) 0.5 ⁇
- Vitamin E 0.25 mg/L
- Lipid mixture (Sigma, L5416) 1 ml/L
- Example 1 Acceleration of stem cell proliferation
- the conventional medium formulation for culturing stem cells was: DMEM/F12 minimal medium, 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- human stem cells derived from three tissues and organs of fat, bone marrow and umbilical cord are used in this embodiment.
- ADSC, BMSC, UMBSC were used for in vitro cell culture experiments.
- the cell seeding density was controlled to be between 10 and 20%.
- the cells were cultured for 2 hours at room temperature or overnight at 4 ° C before inoculation, and cultured in the medium (37 ° C, 5% CO 2 ) after inoculation.
- Example 2 The potential of mesenchymal stem cells to be divided into chondrocytes in vitro is analyzed to examine the effect of stem cells on their differentiation potential after 10 passages of the medium described in the present invention, which is described in the literature.
- the dried granules are grown to a suitable density (cell density 20-80%), and the chondrogenic induction medium (1% FBS DMEM/F12 medium, 10 g/L TGF- ⁇ 1 , 50 nM vitamin C, 6.25) is added. Mg/L insulin, 1% double antibody), change the solution once a day for a total of 2-3 weeks. After the induction was successful, Alcian blue staining was performed. The 1% Alcian Blue formula used: Weigh O. lg Alcian Blue, dissolve in 10 ml of 3% glacial acetic acid solution, and after the precipitate is dissolved, filter it with a 0.22 ⁇ filter before use.
- the chondrogenic induction medium 1% FBS DMEM/F12 medium, 10 g/L TGF- ⁇ 1 , 50 nM vitamin C, 6.25
- Mg/L insulin, 1% double antibody change the solution once a day for a total of 2-3 weeks.
- Alcian blue staining was performed.
- the specific staining method is: wash the cell culture medium and wash it with PBS; add 4% poly-furfural solution for 30 minutes, then wash 2-3 times with PBS; add new 1% Alcian blue dye solution 40 Minutes, wash 3 times with PBS (2 minutes each time) and observe under a microscope.
- the number of positive cells was counted after staining for chondrocytes.
- FIG. 2 the ratio of stem cells cultured in the medium described by the present invention (solid column) to stem cells cultured in a conventional serum medium (open cylinder) to chondrocytes is about 90%, so A similar ability to chondrocytes. Data are mean SEM of three independent experiments.
- adipose-derived stem cells as described in the literature are induced by fat and oil red 0 staining method.
- the differentiation experiments of human adipocytes (ADSC, BMSC, UMBSC) derived from fat, bone marrow and umbilical cord tissue were determined as described in the literature (Y G et al., Methods in Molecular). Biology, 2011, Volume 702, Part 3, 193-200; Bunnell BA et al" Methods. Volume 45, Issue 2, June 2008, Pages 115-120; Gimble JM & Guilak F. Cytotherapy. 2003, Vol.5, No .5, Pages 362-369).
- the specific method is to change the density of the stem cells to about 80% to form the adipogenic medium.
- the formula of the adipogenic medium is: 1% FBS DMEM/F12 medium, 1 ⁇ Dexamethasone, 200 ⁇ indomethacin, 0.5 ⁇ 3-isobutyl-1-indenylxanthine (IBMX), 10 g/ml insulin.
- Oil red 0 staining solution is made up of oil red 0, oil red 0 storage : Weigh 0.5 g of Oil Red O was added to 100 ml of isopropanol, 0.22 ⁇ filter; Oil Red O working solution: absorption Add 6ml of Oil Red O stock solution to 4 ml of distilled water and mix well. Specifically, after the adipogenic induction was successful, the medium was aspirated and washed twice with PBS; stained with freshly prepared oil red 0 staining solution for 1 hour; the staining solution was removed, washed 3 times with PBS for 2 min each time, and observed with a microscope .
- the number of positive cells counted after staining for adipocytes The statistical results are shown in Fig. 3.
- the ratio of stem cells cultured in the medium described by the present invention (solid column) to stem cells cultured in a conventional serum medium (open cylinder) to chondrocytes is 80-90%. Between, therefore, the ability to express similar fat cells.
- Data are mean SEM of three independent experiments. The results indicate that after the stem cells are cultured in the medium described in the present invention, the efficiency of adipogenic cells is comparable to the efficiency of adipogenic cells cultured in a conventional serum stem cell culture medium, and thus the cultured stem cells described in the present invention can maintain their cells. The potential to differentiate into fat cells.
- the three tissues of the fat, the bone marrow and the umbilical cord were determined according to the method described in the literature.
- Human stem cells derived from human stem cells (ADSC, BMSC, UMBSC) were expanded for 10 generations and differentiated into neuroblasts ( Wu H et al. Proc Natl Acad Sci US A. 2007 Aug 21 ; 104(34): 13821-6. ) Specifically, when the cells are to be 70% ⁇ 80% cell density after planting, the medium for differentiation is added, that is, DMEM/F12, 10% FBS, 1 ⁇ 2 mM BME, and the medium is aspirated after 24 hours, washed with PBS.
- DMEM / F12 N2 additive ratio of 1:1.
- NSE neuron-specific enolase
- NF neurofilament
- the ratio of stem cells cultured in the medium described by the present invention (solid column) to stem cells cultured in a conventional serum medium (open cylinder) into nerve cells is 60-70%. Left and right, thus showing a similar ability to enter the nerve. Data are mean SEM (P ⁇ 0.001) for three independent experiments. The results indicate that after the stem cells are cultured in the medium described in the present invention, the efficiency of the neuroblasts is comparable to the efficiency of the neuroblasts after the culture of the conventional serum stem cell culture medium, so that the culture medium-preserved stem cells described in the present invention can be maintained. Its potential to differentiate into nerve cells.
- the three tissues of the fat, the bone marrow and the umbilical cord were determined according to the method described in the literature. Differentiation of retinal epithelial cells (RPE) after 10 passages of human stem cells (ADSC, BMSC, UMBSC) was amplified (Osakada F et al, Nat Biotechnol. 2008 Feb;26(2):215-24.). The number of positive cells counted after staining for RPE cell markers. The statistical results are shown in Figure 5.
- RPE retinal epithelial cells
- the medium-cultured stem cells (solid bars) described in the invention are different from the conventional serum medium-cultured stem cell cells (open cylinders) into RPE cells at a ratio of 55-70%, thus exhibiting a similar RPE.
- the ability of cells. indicate that after the stem cells are cultured in the medium described in the present invention, the efficiency of the RPE cells is comparable to that of the conventional serum stem cell medium, and thus the cultured stem cells described in the present invention can maintain their potential to differentiate into RPE cells. .
- a mouse model of retinal photoreactive retinal diseases was selected in this example (Boles C et al., Nature. 1990 Oct 18; 347(6294): 677-80.), after 10 generations of expanded human, stem cells (ADSC, BMSC or UMBSC) derived from three tissues and organs of the umbilical cord were expanded and implanted into the retina, Histologically, the number of photoreceptor cells was measured to determine their protective effect on photoreceptor cells of the retina. The specific results are shown in Fig. 6.
- the stem cells cultured in the stem cell culture medium provided by the present invention can be differentiated into functional cells under suitable conditions, such as, but not limited to, fat cells, as in stem cells cultured in a conventional medium. Chondrocytes, nerve cells, heart Myocytes, retinal pigment cells, and photoreceptor cells of the retina. Moreover, cell transplantation has a good protective effect on degenerative tissue or organ models, including but not limited to retinal degenerative models with genetic mutation modifications. Moreover, it can be seen from the test results that the serum-free stem cell culture medium provided by the present invention is more suitable for culturing stem cells than conventional media.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
提供了一种干细胞培养基及其应用和干细胞培养方法,所述干细胞培养基中不含血清,包含氨基酸、维生素、盐类、脂类、细胞因子和蛋白多肽。所述干细胞培养基适合于快速培养人及哺乳动物组织来源的干细胞,包括但不限于脂肪间充质干细胞、骨髓间充质干细胞和脐带血干细胞。采用该干细胞培养基与普通培养基相比,能让细胞的扩增速度提高3-5倍,延长传代次数,而且能很好的保持干细胞的潜能性。
Description
一种干细胞培养基及其应用和干细胞培养方法 技术领域
本发明涉及细胞培养领域,尤其涉及一种干细胞培养基及其应用 和干细^ ^培养方法。 背景技术
诸多研究表明干细胞不仅可以自我更新,在条件合适的情况下能 分化成其他功能细胞,因此干细胞有望成为治疗人类疑难疾病的有效 手段。 然而, 干细胞在正常成体组织中含量甚微, 在体外如何快速扩 增与培养干细胞培养是研究干细胞的作用机制及探索其在治疗人类 疾病治疗方法的重要技术。
干细胞尽量含量甚微, 但广泛分布于哺乳动物的各个组织器官, 这些组织或器官包括但不局限于骨髓、 脐带、 脂肪组织、 脑组织、 视 网膜、 心脏、 肝脏、 肺以及皮肤等。 大量研究表明, 这些低含量的干 细胞可在体外通过适当的方法进行进一步扩增,最常规的一种培养干 细胞的培养基就是添加有胎牛血清的培养基。 然而, 采用这种培养基 培养的干细胞, 不仅生长比较緩慢, 而且传递次数超过 5代之后其分 化成功能细胞的潜能大大降低,牛血清批次存在潜在的不重复性也大 大影响了其规模化; 另一方面, 牛血清相对于人是异源性的东西, 从 而限制了其在临床上的应用。 因此,探索快速扩增干细胞而又不影响
其潜能的培养条件及其培养基组成的优化组合是非常重要的研究内 容。 发明内容
鉴于上述现有技术的不足,本发明的目的在于提供一种干细胞培 养基及其应用和干细胞培养方法, 旨在解决采用现有添加有牛血清的 培养基培养干细胞存在生长緩慢且细胞潜能会传代次数的增加而大 大降低的问题。
本发明的技术方案如下:
一种干细胞培养基, 其中, 所述干细胞培养基中不含血清, 所述 干细胞培养基包括氨基酸、 维生素、 盐类、 脂类、 细胞因子和蛋白多 肽;
其中, 所述氨基酸包括丙氨酸、 精氨酸、 天冬酰胺、 天冬氨酸、 半胱氨酸、 谷氨酸、 甘氨酸、 组氨酸、 异亮氨酸、 亮氨酸、 赖氨酸、 曱硫氨酸、 苯丙氨酸、 脯氨酸、 丝氨酸、 苏氨酸、 色氨酸、 酪氨酸、 缬氨酸及谷氨酰胺;
所述细胞因子和蛋白多肽包括成纤维细胞生长因子 1、 成纤维细 胞生长因子 2、 表皮生长因子、 血小板衍生生长因子、 胰岛素、 胰岛 素样生长因子 1、 血管内皮细胞生长因子、 胎盘生长因子、 白血病抑 制因子、 干细胞因子、 转铁蛋白和人血清白蛋白;
所述维生素包括生物素、 氯化胆碱、 D-泛酸钙、 叶酸、 肌醇、 烟 酰胺、 吡哆醇盐酸盐、 核黄素、 盐酸石克氨、 辅酶 Q10、 维生素 B12、
腐胺二盐酸盐、 维生素 C和维生素 E;
所述脂类包括地塞米松、 油酸、 胆固醇、 乙醇胺、 亚油酸、 硫辛 酸和脂质混合物;
所述盐类包括碳酸氢钠、 氯化钙、 氯化钾、 氯化镁、 硫酸镁、 氯 化钠、 一水磷酸二氢钠、 磷酸氢二钠和丙酮酸钠;
所述干细胞培养基还包括抗氧化剂、 D-葡萄糖、牛磺酸、肝素钠。 所述的干细胞培养基, 其中, 所述干细胞培养基以 1升计算, 包 括以下组分:
丙氨酸 0.01' -0.25mM
精氨酸 0.4〜 10 mM
天冬酰胺 0.11' -2.75 mM
天冬氨酸 0.03' -0.75 mM
半胱氨酸 0.03' -0.75 mM
谷氨酸 0.03' -0.75 mM
甘氨酸 0.05' -1.25 mM
组氨酸 0.03 -0.75 mM
异亮氨酸 0.5〜 12.5 mM
亮氨酸 0.24 〜6 mM
赖氨酸 0·2〜 5 mM
曱硫氨酸 0.12 〜3 mM
苯丙氨酸 0.21 -5.25 mM
脯氨酸 0.004〜0.1 mM
丝氨酸 0·15〜3.5 mM
苏氨酸 0.06〜1.5 mM
色氨酸 0.02-0.5 mM
酪氨酸 0.03-0.75 mM
缬氨酸 0.28-7 mM
谷氨酰胺 0.8〜20 mM
表皮生长因子 1-10 g/L 纤维细胞生长因子 1 1-10 g/L 纤维细胞生长因子 2 1-10 g/L 胰岛素样生长因子 1 1-10 g/L 白细月包因子 1-10 g/L 血小板衍生生长因子 1-10 g/L 胎盘生长因子 1-10 g/L 干细^ ^因子 1-10 g/L 血管内皮细胞生长因子 1-10 g/L 胰岛素 1〜25 mg/L 转铁蛋白 4〜100 mg/L 入血清白蛋白 0.02-0.5 g/L 生物素 6〜150μΜ 氯化胆碱 12〜300μΜ 叶酸 1.2〜30μΜ 辅酶 Q10 0.2〜5μΜ
地塞米松 2〜50 ηΜ
D-泛酸钠 25μΜ
肌醇 14〜350μΜ 烟酰胺 4〜謂 μΜ
吡哆醇盐酸盐 0·03〜0.75μΜ 核黄素 0.11〜2.75μΜ 盐酸硫氨 0.11〜2.75μΜ 维生素 B12 0.1〜2.5μΜ 腐胺二盐酸盐 0.1〜2.5μΜ 维生素 C 2-50 mg/L 维生素 E 0·05〜1.25 mg/L 肝素钠 0.08-2 g/L
D-葡萄糖 3.6〜90 mM 还原性谷胱甘肽 0.0002〜0.005 mg/L 牛橫酸 0.00144-0.36 g/L β-巯基乙醇 0.0卜 0.25 g/L 酚红 1.62-40.5 mg/L 油酸 0.5〜12.5 mg/L 亚油酸 0.5-7.5 mg/L 硫辛酸 0.02-0.5 mg/L 脂质混合物 0.2〜5 ml/L
胆固醇 1〜25 mg/L
乙醇胺 12~300μ1/Ε
碳酸氢钠 2.32〜58 mM
氯化钙 0.0168〜0.42 mM
氯化钾 0.832-20.8 mM
氯化镁 0.06〜1.5 mM
硫酸镁 0.0814〜2.035 mM
氯化钠 24.122-603.55 mM
0層6〜2.265 mM
0.1-2.5 mM
丙酮酸钠 0.1〜2.5 mM 。
丙氨酸 0.05 mM
精氨酸 2.00 mM
天冬酰胺 0.55 mM
天冬氨酸 0.4 mM
半胱氨酸 0.15 mM
谷氨酸 0.15 mM
甘氨酸 0.25 mM
组氨酸 0.15 mM
异亮氨酸 2.50 mM
亮氨酸 1.20 mM
赖氨酸 1.00 mM
曱硫氨酸 0.60 mM
苯丙氨酸 1.05 mM
脯氨酸 0.02 mM
丝氨酸 0.70 mM
苏氨酸 0.30 mM
色氨酸 0.10 mM
酪氨酸 0.15 mM
缬氨酸 1.4 mM
谷氨酰胺 4 mM
表皮生长因子 1-10 g/L
纤维细胞生长因子 1 1 -10 g/L 纤维细胞生长因子 2 1 -10 g/L 胰岛素样生长因子 1 1 -10 g/L 白细月包因子 1- 10 g/L 血小板衍生生长因子 1- 10 g/L 胎盘生长因子 1- 10 g/L 干细^ ^因子 1- 10 g/L 血管内皮细胞生长因子 1- 10 g/L 胰岛素 5 mg/L
转铁蛋白 20 mg/L
人血清白蛋白 0.1 g/L
生物素 30 μΜ
氯化胆碱 60 μΜ
叶酸 6 μΜ
辅酶 Q10 1 μΜ
地塞米松 10 ηΜ
D-泛酸钠 5 μΜ
肌醇 70 μΜ
烟酰胺 20 μΜ
吡哆醇盐酸盐 0.15 μΜ 核黄素 0.55 μΜ 盐酸疏氛 0.55 μΜ 维生素 B12 0.5 μΜ 腐胺二盐酸盐 0.5 μΜ 维生素 C 10 mg/L 维生素 E 0.25 mg/L 肝素钠 0.4g/L
D-葡萄糖 18 mM 还原性谷胱甘肽 0.001 mg/L 牛磺酸 0.0072 g/L β-巯基乙醇 0.05 g/L 酚红 8.1 mg/L 油酸 2.50 mg/L
亚油酸 1.5 mg/L
硫辛酸 0.1 mg/L
脂质混合物 1 ml/L
胆固醇 5 mg/L
乙醇胺 60 μΙ/L
碳酸氢钠 11.6 mM
氯化钙 0.084 mM
氯化钾 4.16 mM
氯化镁 0.3 mM
硫酸镁 0.407 mM
氯化钠 120.61 mM
一水磷酸二氢钠 0.453 mM
磷酸氢二钠 0.5 mM
丙酮酸钠 0.5 mM。
一种如上所述的干细胞培养基的应用, 其中, 将所述干细胞培养 基用于培养千细胞。
所述的千细胞培养基的应用, 其中, 所述干细胞包括但不局限于 人与哺乳动物来源的干细胞。
所述的干细胞培养基的应用, 其中, 所述干细胞从各种组织或器 官里分离得到; 所述组织与器官包括但不局限于骨髓、 脐带、 脂肪组 织、 脑组织、 视网膜、 心脏、 肝脏、 肺以及皮肤。
一种采用如上所述的干细胞培养基的培养干细胞的方法, 其中,
在进行培养干细胞前将用于促使干细胞贴壁的材料包被培养 ,依次 所述加入所述干细胞培养基和干细胞。
所述的培养干细胞的方法, 其中, 所述用于促使干细胞贴壁的材 料为胶原蛋白、 明胶、 多聚赖氨酸、 纤粘连蛋白、 层粘连蛋白、 玻表 粘连蛋白的一种或多种混合物。
有益效果: 本发明所提供的干细胞培养基, 不含血清, 适合于快 速培养人及哺乳动物组织来源的干细胞,包括但不局限于脂肪间充质 干细胞、 骨髓间充质干细胞和脐带血干细胞。 该培养基能让细胞的扩 增速度提高 3-5倍, 但又不影响其分化的潜能。 采用该干细胞培养基 与普通培养基相比, 不仅能更快速扩增不同来源的干细胞, 延长了传 代次数, 而且又能艮好的保持干细胞的潜能性。 附图说明
图 la为本发明实施例 1 中采用本发明干细胞培养基与常规培养 基培养 ADSC的干细胞扩增速度的检测结果示意图。
图 lb为本发明实施例 1中采用本发明干细胞培养基与常规培养 基培养 BMSC的干细胞扩增速度的检测结果示意图。
图 lc为本发明实施例 1 中采用本发明干细胞培养基与常规培养 基培养 UMBSC的干细胞扩增速度的检测结果示意图。
图 2为本发明实施例 2中经过本发明干细胞培养基与常规培养基 培养的 ADSC、 BMSC和 UMBSC体外分化成软骨细胞潜能的检测结 果示意图。
图 3为本发明实施例 3中经过本发明干细胞培养基与常规培养基 培养的 ADSC、 BMSC和 UMBSC体外分化成脂肪细胞潜能的检测结 果示意图。
图 4为本发明实施例 4中经过本发明干细胞培养基与常规培养基 培养的 ADSC、 BMSC和 UMBSC体外分化成神经细胞潜能的检测结 果示意图。
图 5为本发明实施例 5中经过本发明干细胞培养基与常规培养基 培养的 ADSC、 BMSC和 UMBSC体外分化成视网膜上皮细胞潜能的 检测结果示意图。
图 6 为本发明实施例 6 中经过本发明干细胞培养基培养的 ADSC、 BMSC和 UMBSC移植之后对感光细胞退行性视网膜模型的 保护作用的检测结果示意图。 具体实施方式
本发明提供一种干细胞培养基及其应用和干细胞培养方法,为使 本发明的目的、 技术方案及效果更加清楚、 明确, 以下对本发明进一 步详细说明。应当理解, 此处所描述的具体实施例仅仅用以解释本发 明, 并不用于限定本发明。
本发明所提供的干细胞培养基中不含血清,其配方涉及到添加氨 基酸、 维生素、 盐类、 脂类、 细胞因子和蛋白多肽, 细胞培养方法涉 及到促进细胞贴壁材料的使用。 该方法与普通培养基相比, 不仅能更 快速扩增不同来源的干细胞, 延长了传代次数, 而且又能艮好的保持
干细胞的潜能性。所述干细胞培养基适合用于快速培养人及哺乳动物 组织来源的干细胞, 包括但不局限于脂肪间充质干细胞、 骨髓间充质 干细胞和脐带血干细胞。
具体地, 所述干细胞培养基包括氨基酸、 维生素、 盐类、 脂类、 细胞因子和蛋白多肽;
其中, 所述氨基酸包括丙氨酸、 精氨酸、 天冬酰胺、 天冬氨酸、 半胱氨酸、 谷氨酸、 甘氨酸、 组氨酸、 异亮氨酸、 亮氨酸、 赖氨酸、 曱硫氨酸、 苯丙氨酸、 脯氨酸、 丝氨酸、 苏氨酸、 色氨酸、 酪氨酸、 缬氨酸及谷氨酰胺;
所述细胞因子和蛋白多肽包括成纤维细胞生长因子 1 ( FGF1 )、 成纤维细胞生长因子 2 ( FGF2 )、 表皮生长因子(EGF )、 血小板衍生 生长因子(PDGF )、 胰岛素(insulin ), 胰岛素样生长因子 1 ( IGF1 )、 血管内皮细胞生长因子 (VEGF )、 胎盘生长因子 (PGF )、 白血病抑 制因子( LIF )、 干细胞因子( SCF )、 转铁蛋白 ( transferrin )和人血 清白蛋白 (HSA );
所述维生素包括生物素、 氯化胆碱、 D-泛酸钙、 叶酸、 肌醇、 烟 酰胺、 吡哆醇盐酸盐、 核黄素、 盐酸石克氨、 辅酶 Q10、 维生素 B12、 腐胺二盐酸盐、 维生素 C和维生素 E;
所述脂类包括地塞米松、 油酸、 胆固醇、 乙醇胺、 亚油酸、 硫辛 酸和脂质混合物( Lipid mixture ) ( Sigma, L5416 );
所述微量元素包括绿化钴、 亚硒酸钠、 氯化镍、 氯化锰、 乙二胺 四乙酸钠盐、 七钼酸铵、 氯化铝、 硫酸铬钾、 硫酸铜、 硝酸铁、 硫酸
亚铁或石克酸锌;
其他小分子物质包括抗氧化剂(β-巯基乙醇、 还原型谷胱甘肽)、
D-葡萄糖、 牛磺酸、 肝素钠。
进一步地, 所述干细胞培养基以 1升计算, 包括以下组分:
辅酶 Q10 (Coenzyme Q10) 0.2~5μΜ
地塞米松 (dexamethasone) 2~50 ηΜ
D-泛酸钠 (Na pantotenate) 1~25μΜ
肌醇 (i-lnositol) 14~350μΜ
烟酰胺 (Niacinamide) 4~100μΜ
吡哆醇盐酸盐 (Pyridoxine hydrochloride) 0.03~0.75μΜ
核黄素 (Riboflavin) 0.11~2.75μΜ
盐酸硫氨 (Thiamine hydrochloride) 0.11~2.75μΜ
维生素 B12 (Vitamin B12) 0.1~2.5μΜ
腐胺二盐酸盐 (Putresicine.2HCI) 0.1~2.5μΜ
维生素 C (Vitamin C) 2~50 mg/L
维生素 E (Vitamin E) 0.05-1.25 mg/L
肝素钠 (Heparin sodium) 0.08-2 g/L
D-葡萄糖 (D-Glucose) 3.6-90 mM
还原性谷胱甘肽 (Reduced Glutathione) 0.0002-0.005 mg/L
牛磺酸 (Taurine) 0.00144-0.36 g/L
β-巯基乙醇 (ΒΜΕ) 0.01~0.25 g/L
酚红 (Phenol red) 1.62-40.5 mg/L
油酸 (Oleic acid) 0.5-12.5 mg/L
亚油酸 (Linoleic acid) 0.5-7.5 mg/L
硫辛酸 (Lipoic acid) 0.02-0.5 mg/L
脂质混合物 (Lipid mixture) (Sigma, L5416) 0.2-5 ml/L
胆固醇 (Cholesterol) 1~25 mg/L
乙醇胺 (Ethanolamine) 12~300μΙ八
碳酸氢钠 (NaHC03) 2.32~58 mM
氯化钙 (CaCI2) 0.0168-0.42 mM
氯化钾 (KCI) 0.832-20.8 mM
氯化镁 (MgCI2) 0.06-1.5 mM
硫酸镁 (MgS04) 0.0814-2.035 mM
氯化钠 (NaCI) 24.122~603.55 mM
磷酸二氢钠 (一水) (NaH2P04.H20) 0.0906-2.265 mM
磷酸氢二钠 (Na2HP04) 0.1-2.5 mM
丙酮酸钠 (Sodium pyruvate) 0.1-2.5 mM
本发明所提供的培养基适合用于快速培养人及哺乳动物组织来 源的干细胞, 包括但不局限于脂肪间充质干细胞、 骨髓间充质干细胞 和脐带血干细胞。 该培养基能让细胞的扩增速度提高 3-5倍, 但又不 影响其分化的潜能。
经本发明所提供的培养基培养的干细胞像常规培养基培养的干 细胞一样能 4艮好的分化成其功能细胞,其功能细胞包括但不局限于脂 肪细胞、 软骨细胞、 神经细胞、 视网膜色素上皮细胞、 视网膜感光细 胞。一方面, 经本发明所描述的培养基培养的干细胞像常规培养基培 养过的干细胞一样,细胞移植后对退行性组织或器官具有艮好的保护 作用; 另一方面, 经本发明所描述的培养基培养过的干细胞像常规培 养基培养的干细胞一样, 经移植后可以恢复原有的功能。
本发明中还提供的干细胞培养基的应用,将所述干细胞培养基用 于培养干细胞, 所述干细胞包括但不局限于人与哺乳动物(如小鼠、 大鼠、 兔)来源的干细胞, 所述干细胞可以从各种组织或器官里分离 到。 组织与器官包括但不局限于骨髓、 脐带、 脂肪组织、 脑组织、 视 网膜、 心脏、 肝脏、 肺以及皮肤。
当采用本发明所提供的干细胞培养基培养干细胞时,由于本发明 培养基中不含有能使干细胞贴壁生长的物质, 因此, 在培养干细胞以 前需要使用促使干细胞贴壁材料, 如胶原蛋白、 明胶、 多聚赖氨酸、 纤粘连蛋白、 层粘连蛋白、 玻表粘连蛋白的一种或多种混合物。 因为 带血清的培养基里含有这些东西, 所以不需要加; 而本发明不带血清 的干细胞培养基不含这些东西, 所以需要在培养干细胞前, 将所述贴 壁材料包被培养 jni, 之后才依次加本发明干细胞培养基和干细胞, 然 后按照常规培养方法进行培养干细胞。
以下通过实施例对本发明做进一步说明书,在实施例 1〜6中, 所 采用的干细胞培养基以 1升计算, 包括以下组分:
成分 浓度或量
Ala (丙氨酸) 0.05 mM
Arg (精氨酸) 2.00 mM
Asn (天冬酰胺) 0.55 mM
Asp (天冬氨酸) 0.4 mM
Cys (半胱氨酸) 0.15 mM
Glu (谷氨酸) 0.15 mM
Gly (甘氨酸) 0.25 mM
His (组氨酸) 0.15 mM
He (异亮氨酸) 2.50 mM
Leu (亮氨酸) 1.20 mM
Lys (赖氨酸) 1.00 mM
Met (甲硫氨酸) 0.60 mM
Phe (苯丙氨酸) 1.05 mM
Pro (脯氨酸) 0.02 mM
Ser (丝氨酸) 0.70 mM
Thr (苏氨酸) 0.30 mM
Trp (色氨酸) 0.10 mM
Tyr (酪氨酸) 0.15 mM
Val (缬氨酸) 1.4 mM
Gin (谷氨酰胺) 4 mM 表皮生长因子 (EGF) 1-10 μ^Ι 纤维细胞生长因子 1 (FGF1) 1-10 μ^Ι 纤维细胞生长因子 2 (FGF2) 1-10 μ^Ι 胰岛素样生长因子 1 (IGF1) 1-10 μ^Ι 白细胞因子 (LIF) 1-10 μ^Ι 血小板衍生生长因子 (PDGF) 1-10 μ^Ι 胎盘生长因子 (PGF) 1-10 μ^Ι 干细胞因子 (SCF) 1-10 μ^Ι 血管内皮细胞生长因子 (VEGF) 1-10 μ^Ι 胰岛素 (insulin) 5mg/L 转铁蛋白 (transferrin) 20 mg/L 人血清白蛋白 (HSA) 0.1g/L 生物素 (biotin) 30 μΜ 氯化胆碱 (Choline chloride) 60 μΜ 叶酸 (Folic acid) 6 μΜ 辅酶 Q10 (Coenzyme Q10) 1 μΜ 地塞米松 (dexamethasone) 10 ηΜ
D-泛酸钠 (Na pantotenate) 5 μΜ 肌醇 (i-lnositol) 70 μΜ 烟酰胺 (Niacinamide) 20 μΜ 吡哆醇盐酸盐 (Pyridoxine hydrochloride) 0.15 μΜ 核黄素 (Riboflavin) 0.55 μΜ
盐酸硫氨 (Thiamine hydrochloride) 0.55 μΜ
维生素 B12 (Vitamin B12) 0.5 μΜ
腐胺二盐酸盐 (Putresicine.2HCI) 0.5 μΜ
维生素 C (Vitamin C) 10 mg/L
维生素 E (Vitamin E) 0.25 mg/L
肝素钠 (Heparin sodium) 0.4g/L
D-葡萄糖 (D-Glucose) 18 mM
还原性谷胱甘肽 (Reduced Glutathione) 0.001 mg/L
牛磺酸 (Taurine) 0.0072 g/L
β-巯基乙醇 (ΒΜΕ) 0.05 μ^ιΐ
酚红 (Phenol red) 8.1mg/L
油酸 (Oleic acid) 2.50 mg/L
亚油酸 (Linoleic acid) 1.5 mg/L
硫辛酸 (Lipoic acid) 0.1 mg/L
脂质混合物 (Lipid mixture) (Sigma, L5416) 1 ml/L
胆固醇 (Cholesterol) 5 mg/L
乙醇胺 (Ethanolamine) 60 μΙ.Ί
碳酸氢钠 (NaHC03) 11.6 mM
氯化钙 (CaCI2) 0.084 mM
氯化钾 (KCI) 4.16 mM
氯化镁 (MgCI2) 0.3 mM
硫酸镁 (MgS04) 0.407 mM
氯化钠 (NaCI) 120.61 mM
磷酸二氢钠 (一水) (NaH2P04.H20) 0.453 mM
磷酸氢二钠 (Na2HP04) 0.5 mM
丙酮酸钠 (Sodium pyruvate) 0.5 mM
实施例 1. 对干细胞增殖的加速作用 培养干细胞的常规培养基配方为: DMEM/F12基本培养基, 10% 胎牛血清(FBS)。 为比较本发明所描述的培养基与为检查本发明所 描述的培养基对人干细胞培养的扩增速度的影响,本实施例中选用了 脂肪、骨髓间以及脐带三种组织器官来源的人干细胞(ADSC,BMSC, UMBSC)做体外细胞培养实验。 细胞接种密度控制在 10-20%之间, 接种前培养 用细胞贴壁材料室温处理 2小时或 4°C保温过夜, 接种 后加入培养基培养(37 °C, 5%C02)。 每隔 12 小时通过 MTT 法测
一次细胞密度。 检测结果如图 1〜图 3所示, 经本发明描述的培养基 培养的干细胞(实心柱形)比经常规血清培养基培养的细胞(空心柱 形)表现出更快的扩增速度, 数据为三次独立实验的平均值士 SEM ( P<0.001 )。 研究结果表明, 采用本发明所描述的干细胞培养基对干 细胞的扩增速度与常规的血清培养基相比,达到 100% 细胞密度的时 间大大缩短。
实施例 2. 增殖后间充质干细胞体外分为成软骨细胞的潜能分析 为检查干细胞经本发明所描述的培养基扩增 10代后对其分化潜 能的影响, 本实施例中按文献所描述的方法测定了脂肪、 骨髓间以及 脐带三种组织器官来源的人干细胞 (ADSC, BMSC, UMBSC)扩增之 后的成软骨细胞分化实验 ( Estes BT et al. Nat Protoc 2010; 5: 1294-1311 ; Awad HA et al., Biomaterials. 2004 Jul;25(16):3211-22; Cheng NC et al., Tissue Eng Part A. 2009 Feb; 15(2) :231-41 )。 待干细月包 长到合适密度(细胞密度 20-80% ),加入成软骨诱导培养基 ( 1% FBS 的 DMEM/F12培养基, 10 g/L TGF- β 1 , 50 nM 维生素 C, 6.25 mg/L 胰岛素, 1% 双抗), 每天换一次液, 总共诱导 2-3 周。 诱导成功之 后进行阿尔新蓝染色。 所采用的 1%阿尔新蓝配方: 称取 O. lg阿尔新 蓝, 溶于 10ml 3%冰醋酸溶液, 待沉淀溶解后, 用 0.22 μιη的滤器过 滤后再使用。 具体染色方法是, 吸去细胞培养基后用 PBS 洗一遍; 再加入 4% 多聚曱醛溶液固定 30 分钟后用 PBS洗 2-3遍;加入新配 的 1% 阿尔新蓝染液染色 40 分钟, 用 PBS洗 3次(每次 2分钟 ), 置显微镜下观察。对软骨细胞染色后统计阳性细胞的数量。 统计结果
如图 2所示, 经本发明描述的培养基培养的干细胞(实心柱形)与经 常规血清培养基培养的干细胞细胞 (空心柱形 )分化成软骨细胞的比 率均在 90%左右, 因此表现出相似的成软骨细胞的能力。 数据为三 次独立实验的平均值士 SEM。 结果表明, 干细胞经本发明所描述的培 养基培养之后,成软骨细胞的效率与常规干细胞培养基培养后的成软 骨细胞的效率相媲美,因此本发明所描述的培养基培养的干细胞能保 持其分化成软骨细胞的潜能。
实施例 3.成脂肪细胞的潜能分析
为进一步检查干细胞经本发明所描述的培养基扩增 10代后对其 分化潜能的影响, 本实施例中按文献所描述的脂肪来源的干细胞 ( ADSC )成脂诱导及油红 0染色方法我们测定了按文献所描述的方 法测定了脂肪、 骨髓间以及脐带三种组织器官来源的人干细胞 (ADSC, BMSC, UMBSC)扩增之后成脂肪细胞的分化实验( Yu G et al., Methods in Molecular Biology, 2011, Volume 702, Part 3, 193-200; Bunnell BA et al" Methods. Volume 45, Issue 2, June 2008, Pages 115-120; Gimble JM & Guilak F. Cytotherapy. 2003,Vol.5, No.5,Pages 362-369)。 具体的方法是, 待干细胞密度为 80% 左右换成成脂培养 基进行诱导, 成脂培养基的配方为: 1% FBS的 DMEM/F12培养基、 1 μΜ地塞米松、 200 μΜ 吲哚美辛、 0.5 ηΜ 3-异丁基 -1-曱基黄嘌呤 ( IBMX)、 10 g/ml胰岛素。 两天换一次液, 诱导两周后进行油红 0 染色。 油红 0染色液由油红 0 配置而成, 油红 0储存液: 称取 0.5 g 油红 0加入到 100 ml异丙醇中, 0.22 μιη过滤; 油红 0工作液: 吸
取 6ml油红 O储存液加入到 4 ml蒸馏水中, 混合均匀即可。 具体方 法是, 成脂诱导成功后吸去培养基并用 PBS洗 2遍; 加入新配置的 油红 0染色液染色 1小时;去掉染色液,用 PBS洗 3遍,每次 2 min, 用显微镜观察。对脂肪细胞染色后统计阳性细胞的数量。 统计结果如 图 3所示, 经本发明描述的培养基培养的干细胞(实心柱形)与经常 规血清培养基培养的干细胞细胞 (空心柱形 )分化成软骨细胞的比率 均在 80-90%之间, 因此表现出相似的成脂肪细胞的能力。 数据为三 次独立实验的平均值士 SEM。 结果表明干细胞经本发明所描述的培养 基培养之后,成脂肪细胞的效率与常规血清干细胞培养基培养后的成 脂肪细胞的效率相 美,因此本发明所描述的培养基培养的干细胞能 保持其分化成脂肪细胞的潜能。
实施例 4.成神经细胞的潜能分析
为进一步检查干细胞经本发明所描述的培养基扩增后对其分化 潜能的影响,本实施例中按文献所描述测定了按文献所描述的方法测 定了脂肪、 骨髓间以及脐带三种组织器官来源的人干细胞 (ADSC, BMSC, UMBSC)扩增 10代之后成神经细胞的分化实验 ( Wu H et al. Proc Natl Acad Sci U S A. 2007 Aug 21 ;104(34): 13821-6. )„ 具体地, 细 胞接种植后待达到 70% ~ 80%细胞密度时, 加入诱导分化的培养基, 即 DMEM/F12、 10% FBS、 1 ~ 2 mM BME, 24 h后吸去培养基, PBS 洗 2 次,换成 DMEM、 1 ~ 4 mM BME, 处理 1 ~ 5 h, 吸去培养基, 换成 N2培养基、 20ng bFGF 继续培养。 DMEM/F12: N2添加剂比 例为 1 : 1。 向神经细胞诱导分化 30 min到 10d直接在培养 上进行
免疫细胞化学检查。需检查的神经元特异标志物有神经元特异性烯醇 化酶(NSE) 和神经微丝(NF )。 首先, 0. Ol mol/ L PBS 洗去培养液, 4%的多聚曱醛固定 15 min; PBS 洗 3 次, 每次 5 min; 0. 25% Triton X-100 处理 15 min; PBS 洗 3 次,每次 5 min; 含有 1%羊血清的一 抗 37°C处理 1. 5 h, 4°C 过夜; PBS洗 3 次,每次 5 min; FITC 结合 的兔抗鼠 IgG二抗; 37°C孵育 1 h; PBS 洗 3 次,每次 5 min; 荧光 染色直接在荧光显微镜下观察、 照相; ABC 法染色按说明书进行。对 神经细胞标志物染色后统计阳性细胞的数量。 统计结果如图 4所示, 经本发明描述的培养基培养的干细胞(实心柱形)与经常规血清培养 基培养的干细胞细胞(空心柱形)分化成神经细胞的比率均在 60-70% 左右, 因此表现出相似的成神经的能力。数据为三次独立实验的平均 值士 SEM ( P<0.001 )。 结果表明干细胞经本发明所描述的培养基培养 之后,成神经细细胞的效率与常规血清干细胞培养基培养后的成神经 细胞的效率相媲美,因此本发明所描述的培养基培养的干细胞能保持 其分化成神经细胞的潜能。
实施例 5. 成视网膜上皮细胞的潜能分析
为进一步检查干细胞经本发明所描述的培养基扩增后对其分化 潜能的影响,本实施例中按文献所描述测定了按文献所描述的方法测 定了脂肪、 骨髓间以及脐带三种组织器官来源的人干细胞 (ADSC, BMSC, UMBSC)扩增 10代之后视网膜上皮细胞( RPE ) 的分化实验 ( Osakada F et al , Nat Biotechnol. 2008 Feb;26(2):215-24. )。 对 RPE 细胞标志物染色后统计阳性细胞的数量。 统计结果如图 5所示, 经本
发明描述的培养基培养的干细胞(实心柱形)与经常规血清培养基培 养的干细胞细胞(空心柱形)分化成 RPE细胞的比率均在 55-70%之 间, 因此表现出相似的成 RPE细胞的能力。 结果表明干细胞经本发 明所描述的培养基培养之后, 成 RPE细胞的效率与常规血清干细胞 培养基的效率相媲美,因此本发明所描述的培养基培养的干细胞能保 持其分化成 RPE细胞的潜能。
实施例 6. 增殖后干细胞对细胞退行性模型的保护作用
为检测干细胞经本发明所描述的培养基扩增后对退行性疾病的 治疗作用,本实施例中选用了视网膜感光细胞退行性视网膜疾病小鼠 模型 ( rdl ) ( Bowes C et al., Nature. 1990 Oct 18;347(6294):677-80. ), 将 10代扩增后的脂肪、 骨髓以及脐带三种组织器官来源的人干细胞 (ADSC, BMSC或 UMBSC)扩增之后植入视网膜之后, 组织学检测感 光细胞的数量, 以确定其对视网膜感光细胞的保护作用。 具体结果如 图 6所示, Rdl小鼠经干细胞治疗 1个月之后感光细胞的数量由原来 不到 5%的数量提高到 40%以上, 因此干细胞经本发明所描述的培养 基培养之后保护退行性细胞的能力仍然维持。数据为三次独立实验的 平均值士 SEM ( PO.001 )。 研究表明, 经干细胞细胞移植之后感光细 胞退化明显变慢,而且经本发明所描述的培养基扩增后的干细胞在对 视网膜细胞的保护作用。
综上所述,经本发明所提供的干细胞培养基培养之后的干细胞与 在经常规培养基培养的干细胞一样,在适当的条件下可以分化成功能 细胞, 功能细胞包括但不局限于脂肪细胞、 软骨细胞、 神经细胞、 心
肌细胞、 视网膜色素细胞以及视网膜感光细胞。 而且, 细胞移植后对 退行性组织或器官模型之后具有很好的保护作用,退行性组织或器官 模型包括但不局限于具有遗传突变修饰的视网膜退行性模型。而且从 检测结果可以看出,本发明所提供的不含血清的干细胞培养基较常规 培养基相比更适合用于培养干细胞。
应当理解的是, 本发明的应用不限于上述的举例, 对本领域普通 技术人员来说, 可以根据上述说明加以改进或变换, 所有这些改进和 变换都应属于本发明所附权利要求的保护范围。
Claims
1、 一种干细胞培养基, 其特征在于, 所述干细胞培养基中不含 血清, 所述干细胞培养基包括氨基酸、 维生素、 盐类、 脂类、 细胞因 子和蛋白多肽;
其中, 所述氨基酸包括丙氨酸、 精氨酸、 天冬酰胺、 天冬氨酸、 半胱氨酸、 谷氨酸、 甘氨酸、 组氨酸、 异亮氨酸、 亮氨酸、 赖氨酸、 曱硫氨酸、 苯丙氨酸、 脯氨酸、 丝氨酸、 苏氨酸、 色氨酸、 酪氨酸、 缬氨酸及谷氨酰胺;
所述细胞因子和蛋白多肽包括成纤维细胞生长因子 1、 成纤维细 胞生长因子 2、 表皮生长因子、 血小板衍生生长因子、 胰岛素、 胰岛 素样生长因子 1、 血管内皮细胞生长因子、 胎盘生长因子、 白血病抑 制因子、 干细胞因子、 转铁蛋白和人血清白蛋白;
所述维生素包括生物素、 氯化胆碱、 D-泛酸钙、 叶酸、 肌醇、 烟 酰胺、 吡哆醇盐酸盐、 核黄素、 盐酸石克氨、 辅酶 Q10、 维生素 B12、 腐胺二盐酸盐、 维生素 C和维生素 E;
所述脂类包括地塞米松、 油酸、 胆固醇、 乙醇胺、 亚油酸、 硫辛 酸和脂质混合物;
所述盐类包括碳酸氢钠、 氯化钙、 氯化钾、 氯化镁、 硫酸镁、 氯 化钠、 一水磷酸二氢钠、 磷酸氢二钠和丙酮酸钠;
所述干细胞培养基还包括抗氧化剂、 D-葡萄糖、牛磺酸、肝素钠。
2、 根据权利要求 1所述的干细胞培养基, 其特征在于, 所述干 细胞培养基以 1升计算, 包括以下组分:
丙氨酸 0.0卜 0.25mM 精氨酸 0.4-10 mM 天冬酰胺 0.1卜 2.75 mM 天冬氨酸 0.03-0.75 mM 半胱氨酸 0.03-0.75 mM 谷氨酸 0.03-0.75 mM 甘氨酸 0.05〜1.25 mM 组氨酸 0.03-0.75 mM 异亮氨酸 0.5-12.5 mM 亮氨酸 0.24〜6 mM 赖氨酸 0.2-5 mM 曱硫氨酸 0.12〜3 mM 苯丙氨酸 0.21〜5.25 mM 脯氨酸 0.004〜0.1 mM 丝氨酸 0.15-3.5 mM 苏氨酸 0.06〜1.5 mM 色氨酸 0.02-0.5 mM 酪氨酸 0.03-0.75 mM 缬氨酸 0.28〜7 mM 谷氨酰胺 0.8〜20 mM 表皮生长因子 1- 纤维细胞生长因子 1 1
纤维细胞生长因子 2 1-10 g/L 胰岛素样生长因子 1 1-10 g/L 白细月包因子 1-10 g/L 血小板衍生生长因子 1-10 g/L 胎盘生长因子 1-10 g/L 千细胞因子 1-10 g/L 血管内皮细胞生长因子 1-10 g/L 胰岛素 1〜25 mg/L 转铁蛋白 4〜 100 mg/L 人血清白蛋白 0.02〜0.5g/L 生物素 6〜150μΜ 氯化胆碱 12〜300μΜ 叶酸 1.2〜30μΜ 辅酶 Q10 0.2〜5μΜ
地塞米松 2〜50 ηΜ
D-泛酸钠 1〜25μΜ
肌醇 14〜350μΜ 烟酰胺 4〜100μΜ
吡哆醇盐酸盐 0.03〜0.75μΜ 核黄素 0.11〜2.75μΜ 盐酸硫氨 0.11〜2.75μΜ 维生素 B12 0.1〜2.5μΜ
腐胺二盐酸盐 0.1〜2.5μΜ
维生素 C 2〜50 mg/L 维生素 E 0.05-1.25 mg/L 肝素钠 0.08-2 g/L
D-葡萄糖 3.6〜90 mM 还原性谷胱甘肽 0.0002〜0.005 mg/L 牛石黄酸 0.00144-0.36 g/L β-巯基乙醇 0.0卜 0.25 g/L 酚红 1.62-40.5 mg/L 油酸 0.5〜12.5 mg/L 亚油酸 0.5-7.5 mg/L
硫辛酸 0.02-0.5 mg/L 脂质混合物 0.2〜5 ml/L
胆固醇 1〜25 mg/L
乙醇胺 12~300μ1/ί
碳酸氢钠 2.32〜58 mM
氯化钙 0.0168〜0.42 mM 氯化钾 0.832-20.8 mM 氯化镁 0.06〜1.5 mM
硫酸镁 0.0814〜2.035 mM 氯化钠 24.122-603.55 mM 一水磷酸二氢钠 0.0906-2.265 mM
磷酸氢二钠 0.1〜2.5 mM
丙酮酸钠 0.1-2.5 mM 。
3、 根据权利要求 1所述的干细胞培养基, 其特征在于, 所述干 细胞培养基以 1升计算, 包括以下组分:
丙氨酸 0.05 mM
精氨酸 2.00 mM
天冬酰胺 0.55 mM
天冬氨酸 0.4 mM
半胱氨酸 0.15 mM
谷氨酸 0.15 mM
甘氨酸 0.25 mM
组氨酸 0.15 mM
异亮氨酸 2.50 mM
亮氨酸 1.20 mM
赖氨酸 1.00 mM
曱硫氨酸 0.60 mM
苯丙氨酸 1.05 mM
脯氨酸 0.02 mM
丝氨酸 0.70 mM
苏氨酸 0.30 mM
色氨酸 0.10 mM
酪氨酸 0.15 mM
缬氨酸 1.4 mM
谷氨酰胺 4 mM
表皮生长因子 1-10 g/L
纤维细胞生长因子 1 1-10 g/L 纤维细胞生长因子 2 1-10 g/L 胰岛素样生长因子 1 1-10 g/L 白细月包因子 1-10 g/L 血小板衍生生长因子 1-10 g/L 胎盘生长因子 1-10 g/L 干细 因子 1-10 g/L 血管内皮细胞生长因子 1-10 g/L 胰岛素 5 mg/L
转铁蛋白 20 mg/L
人血清白蛋白 0.1 g/L
生物素 30 μΜ
氯化胆碱 60 μΜ
叶酸 6 μΜ
辅酶 Q10 1 μΜ
地塞米松 10 ηΜ
D-泛酸钠 5 μΜ
肌醇 70 μΜ
烟酰胺 20 μΜ
吡哆醇盐酸盐 0.15 μΜ 核黄素 0.55 μΜ 盐酸硫氨 0.55 μΜ 维生素 B12 0.5 μΜ 腐胺二盐酸盐 0.5 μΜ 维生素 C 10 mg/L 维生素 E 0.25 mg/L 肝素钠 0.4g/L
D-葡萄糖 18 mM 还原性谷胱甘肽 0.001 mg/L 牛磺酸 0.0072 g/L β-巯基乙醇 0.05 g/L 酚红 8.1 mg/L 油酸 2.50 mg/L 亚油酸 I.5 mg/L 碗辛酸 0.1 mg/L 脂质混合物 1 ml/L 胆固醇 5 mg/L 乙醇胺 60 μΙ/L 碳酸氢钠 II.6 mM 氯化钙 0.084 mM 氯化钾 4.16 mM
氯化镁 0.3 mM
硫酸镁 0.407 mM
氯化钠 120.61 mM
一水磚酸二氢钠 0.453 mM
磷酸氢二钠 0.5 mM
丙酮酸钠 0.5 mM。
4、一种如权利要求 1所述的干细胞培养基的应用, 其特征在于: 将所述干细胞培养基用于培养干细胞。
5、 根据权利要求 4所述的干细胞培养基的应用, 其特征在于,
6、 根据权利要求 4所述的干细胞培养基的应用, 其特征在于, 所述干细胞从各种组织或器官里分离得到;所述组织与器官包括但不 局限于骨髓、 脐带、 脂肪组织、 脑组织、 视网膜、 心脏、 肝脏、 肺以 及皮肤。
7、 一种采用如权利要求 1所述的干细胞培养基的培养干细胞的 方法, 其特征在于, 在进行培养干细胞前将用于促使干细胞贴壁的材 料包被培养 , 依次所述加入所述干细胞培养基和干细胞。
8、 根据权利要求 7所述的培养干细胞的方法, 其特征在于, 所 述用于促使干细胞贴壁的材料为胶原蛋白、 明胶、 多聚赖氨酸、 纤粘 连蛋白、 层粘连蛋白、 玻表粘连蛋白的一种或多种混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/885,000 US9321995B2 (en) | 2012-12-20 | 2013-01-31 | Stem cell culture medium and its applications as well as a stem cell culture method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210557941.6 | 2012-12-20 | ||
CN201210557941.6A CN103060264B (zh) | 2012-12-20 | 2012-12-20 | 一种干细胞培养基及其应用和干细胞培养方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014094386A1 true WO2014094386A1 (zh) | 2014-06-26 |
Family
ID=48103163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/071173 WO2014094386A1 (zh) | 2012-12-20 | 2013-01-31 | 一种干细胞培养基及其应用和干细胞培养方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103060264B (zh) |
WO (1) | WO2014094386A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111040945A (zh) * | 2019-12-30 | 2020-04-21 | 安徽惠恩生物科技股份有限公司 | 一种多种类干细胞培养皿及其培养基 |
CN113215095A (zh) * | 2021-05-26 | 2021-08-06 | 生物岛实验室 | 组合物、培养基补充剂以及干细胞培养基及培养方法 |
CN114807028A (zh) * | 2022-06-02 | 2022-07-29 | 广州美健生物技术有限公司 | 一种无血清间充质干细胞培养基及干细胞培养方法 |
WO2023016510A1 (zh) * | 2021-08-13 | 2023-02-16 | 无锡赛比曼生物科技有限公司 | 一种用于低温保存脂肪间充质干细胞的保存液 |
WO2023065384A1 (zh) * | 2021-10-22 | 2023-04-27 | 中国医学科学院生物医学工程研究所 | 一种人间充质干细胞培养基 |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103243070B (zh) * | 2013-04-25 | 2014-07-16 | 苏州佰通生物科技有限公司 | 一种干细胞培养基及其应用 |
CN103243071B (zh) * | 2013-05-09 | 2015-04-29 | 青岛瑞思德生物科技有限公司 | 一种临床级人间充质干细胞无血清完全培养基 |
KR101588394B1 (ko) * | 2013-05-09 | 2016-01-25 | 라정찬 | 줄기세포의 재생능 향상을 위한 배지 조성물 및 이를 이용한 줄기세포의 배양방법 |
CN103333856B (zh) * | 2013-07-25 | 2015-08-26 | 张潇潇 | 人脐带间充质干细胞培养基 |
CN103421740B (zh) * | 2013-07-25 | 2015-05-13 | 奥思达干细胞有限公司 | 一种人骨髓间充质干细胞体外培养扩增方法 |
TWI522467B (zh) * | 2014-05-08 | 2016-02-21 | 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 | 體外小腸幹細胞培養基及培養方法 |
EP3184627B1 (en) * | 2014-08-21 | 2020-12-23 | Ajinomoto Co., Inc. | Culture medium for mesenchymal stem cells |
KR101723633B1 (ko) * | 2014-11-17 | 2017-04-06 | 주식회사 바이오코즈글로벌코리아 | 세포 배양 배지, 표피성장인자 및 소혈청알부민을 포함하는 피부 상태 개선용 화장료 조성물 |
CN104877961A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的人羊膜间充质干细胞培养基及其制备方法 |
CN106701668B (zh) * | 2015-07-22 | 2020-12-29 | 中国医药大学 | 间质干细胞、其纯株化扩张的方法及其应用 |
CN105112363B (zh) * | 2015-08-18 | 2019-03-29 | 广东美赛尔细胞生物科技有限公司 | 一种人脂肪间充质干细胞的无血清培养基及其制备方法 |
CN105112364B (zh) * | 2015-08-18 | 2019-04-02 | 广东美赛尔细胞生物科技有限公司 | 人脂肪间充质干细胞的无血清培养基及其制备方法 |
CN106479978A (zh) * | 2015-10-14 | 2017-03-08 | 北京昱龙盛世生物科技有限公司 | 一种神经干细胞的专用培养基及其培养方法 |
CN106474157B (zh) * | 2015-10-14 | 2021-02-26 | 北京昱龙盛世生物科技有限公司 | 一种肝干细胞注射液及其制备方法 |
CN105567638A (zh) * | 2016-03-01 | 2016-05-11 | 赛百慷(上海)生物技术股份有限公司 | 一种神经干细胞添加剂 |
CN105543174A (zh) * | 2016-03-01 | 2016-05-04 | 赛百慷(上海)生物技术股份有限公司 | 一种肿瘤细胞生长促进添加剂及其使用方法 |
CN105695407B (zh) * | 2016-03-15 | 2019-04-16 | 佰通生物技术(苏州)有限公司 | 一种对干细胞具有活化作用的微量元素组合物及其应用 |
CN106190946A (zh) * | 2016-07-19 | 2016-12-07 | 安徽惠恩生物科技股份有限公司 | 一种用于干细胞扩增的培养基 |
CN106148283A (zh) * | 2016-08-08 | 2016-11-23 | 安徽惠恩生物科技股份有限公司 | 一种造血干细胞贴壁性好的培养基 |
CN106222130A (zh) * | 2016-08-08 | 2016-12-14 | 安徽惠恩生物科技股份有限公司 | 一种提高亚全能干细胞增殖速度的培养基 |
CN106148278A (zh) * | 2016-08-08 | 2016-11-23 | 安徽惠恩生物科技股份有限公司 | 一种间充质干细胞培养基 |
CN106282114A (zh) * | 2016-08-08 | 2017-01-04 | 安徽惠恩生物科技股份有限公司 | 一种快速增殖神经干细胞培养基 |
CN106148275A (zh) * | 2016-08-08 | 2016-11-23 | 安徽惠恩生物科技股份有限公司 | 一种提高表皮干细胞贴壁性的培养基 |
CN106222136A (zh) * | 2016-08-08 | 2016-12-14 | 安徽惠恩生物科技股份有限公司 | 一种用于脂肪干细胞的培养基 |
CN106265741A (zh) * | 2016-10-11 | 2017-01-04 | 青岛大学 | 一种促进皮肤伤口愈合的生物制剂 |
CN106561632A (zh) * | 2016-11-01 | 2017-04-19 | 浙江译美生物科技有限公司 | 用于脂肪干细胞的冻存液及其制备方法以及培养基 |
CN107603945A (zh) * | 2016-11-24 | 2018-01-19 | 广东万海细胞生物科技有限公司 | 一种提高自体脂肪干细胞增殖的新型培养物的制备方法 |
CN108130310A (zh) * | 2016-11-30 | 2018-06-08 | 江阴瑞康健生物医学科技有限公司 | 一种干细胞培养基 |
CN106434549A (zh) * | 2016-12-20 | 2017-02-22 | 江西宜信堂医疗科技有限公司 | 一种无血清干细胞培养基及其制备方法 |
CN106754658A (zh) * | 2016-12-22 | 2017-05-31 | 江西宜信堂医疗科技有限公司 | 一种培养牙髓干细胞的培养基及其制备方法 |
CN106754678A (zh) * | 2016-12-24 | 2017-05-31 | 叶宗耀 | 一种适用于牙髓干细胞体外培养的培养基及其制备方法 |
CN106701665A (zh) * | 2016-12-30 | 2017-05-24 | 东莞惠恩生物工程有限公司 | 人胎盘亚全能干细胞诱导分化为心肌细胞的方法及其应用 |
CN107034184A (zh) * | 2017-05-04 | 2017-08-11 | 济南赛尔生物科技股份有限公司 | 一种用于原代培养脐带间充质干细胞的试剂盒 |
CN107115219A (zh) * | 2017-05-12 | 2017-09-01 | 青岛赛欧凯普图乐生物医药有限公司 | 一种纤维芽母细胞活化液面膜配方 |
CN107058214B (zh) * | 2017-05-27 | 2020-05-08 | 广州润虹医药科技股份有限公司 | 诱导多能干细胞定向分化肾脏细胞的培养基和培养方法 |
CN107475180A (zh) * | 2017-09-25 | 2017-12-15 | 重庆斯德姆生物技术有限公司 | 一种干细胞培养基制备方法 |
CN107586757A (zh) * | 2017-11-01 | 2018-01-16 | 天津昂赛细胞基因工程有限公司 | 一种猪间充质干细胞培养液及其制备方法 |
CN107653228B (zh) * | 2017-11-16 | 2021-05-28 | 四川大学华西医院 | 一种胃癌干细胞培养基及胃癌干细胞分离培养方法 |
CN108410795A (zh) * | 2018-04-12 | 2018-08-17 | 安庆医药高等专科学校 | 一种培养基的配方及制作方法和培养皿 |
CN108559728A (zh) * | 2018-05-08 | 2018-09-21 | 李顺河 | 一种干细胞培养基及其应用和干细胞培养方法 |
CN109136170B (zh) * | 2018-08-20 | 2022-02-18 | 东北农业大学 | 一种适用于鲤鱼三倍体细胞生长的无血清培养基及其应用 |
CN109370988A (zh) * | 2018-11-03 | 2019-02-22 | 章毅 | 干细胞体外扩增培养体系及其方法 |
CN109943524A (zh) * | 2019-03-01 | 2019-06-28 | 宁波医诺生物技术有限公司 | 人间充质干细胞培养基及其制备方法和应用 |
CN109897821A (zh) * | 2019-03-01 | 2019-06-18 | 广州南医大生物工程有限公司 | 一种牙髓干细胞分离及培养方法 |
CN110042079A (zh) * | 2019-04-16 | 2019-07-23 | 深圳大学 | 一种用于培养间充质干细胞的培养基 |
CN110172446A (zh) * | 2019-04-18 | 2019-08-27 | 青岩生物科技(湖州)有限公司 | 一种分离中胚层基质细胞的方法 |
CN110172440A (zh) * | 2019-04-18 | 2019-08-27 | 青岩生物科技(湖州)有限公司 | 一种用于培养中胚层基质细胞的无血清培养基 |
CN110343661B (zh) * | 2019-04-24 | 2021-08-24 | 朗姿赛尔生物科技(广州)有限公司 | 一种人体脂肪干细胞的提取及培养扩增方法 |
CN110295140A (zh) * | 2019-06-04 | 2019-10-01 | 河北贝特赛奥生物科技有限公司 | 一种无血清培养骨髓间充质干细胞的方法 |
CN110800732B (zh) * | 2019-10-10 | 2021-02-02 | 湖南源品细胞生物科技有限公司 | 一种脐带间充质干细胞贮藏液 |
CN110699317A (zh) * | 2019-10-30 | 2020-01-17 | 湖南丰晖生物科技有限公司 | 一种人脐带间充质干细胞无血清培养基及其制备方法与应用 |
CN111004777B (zh) * | 2019-12-10 | 2022-04-29 | 广东国科细胞科技有限公司 | 一种间充质干细胞培养的补料及培养方法 |
CN111440764B (zh) * | 2020-02-21 | 2022-03-29 | 广东国科细胞科技有限公司 | 间充质干细胞的无血清培养基及间充质干细胞的临床级规模化培养方法 |
CN111518764B (zh) * | 2020-06-04 | 2021-10-12 | 惟力维斯(上海)医学科技有限公司 | 一种脂肪干细胞无血清培养基及其制备方法 |
CN111748522A (zh) * | 2020-07-31 | 2020-10-09 | 贵州医科大学附属医院 | 一种干细胞培养基及其应用 |
CN111849904B (zh) * | 2020-07-31 | 2021-05-04 | 浙江科途医学科技有限公司 | 神经母细胞瘤类器官的培养基、培养方法及移植体 |
CN112094844B (zh) * | 2020-09-25 | 2022-06-10 | 成都仕康美生物科技有限公司 | miRNA激动剂及应用、人源间充质干细胞培养基及培养方法 |
CN112300985B (zh) * | 2020-11-03 | 2022-07-01 | 中国人民解放军陆军军医大学第一附属医院 | 一种快速提升哺乳类动物骨髓间充质干细胞增殖效率的增殖培养基及增殖培养方法 |
CN113040133B (zh) * | 2021-03-22 | 2022-03-11 | 北京贝来药业有限公司 | 作为干细胞来源的脐带/胎盘组织采集试剂盒及方法 |
CN112920995A (zh) * | 2021-03-31 | 2021-06-08 | 赵峻岭 | 一种间充质干细胞培养血清加油包及其应用 |
CN113234657B (zh) * | 2021-05-10 | 2022-07-12 | 中国农业大学 | 一种无血清细胞培养基的应用 |
CN113249309A (zh) * | 2021-05-18 | 2021-08-13 | 魏露莹 | 一种使脂肪自动凋亡的技术 |
CN113201491B (zh) * | 2021-06-01 | 2021-12-07 | 四川美科奇生物科技有限公司 | 一种促进干细胞体外增殖和分化的培养方法 |
CN113913294A (zh) * | 2021-10-08 | 2022-01-11 | 南京优而生物科技发展有限公司 | 一种能诱导干细胞分泌细胞因子的方法及其培养装置 |
CN114561348A (zh) * | 2022-03-02 | 2022-05-31 | 北京圣美细胞生命科学工程研究院有限公司 | 一种用于干细胞大规模培养的可溶性微载体 |
CN114317428B (zh) * | 2022-03-09 | 2022-05-27 | 中国中医科学院医学实验中心 | 一种含中药小分子的干细胞无血清培养基及其制备方法 |
CN114831107B (zh) * | 2022-04-11 | 2023-02-24 | 苏州依科赛生物科技股份有限公司 | 一种细胞和组织低温保存液及其配制方法、应用 |
CN117802039A (zh) * | 2024-03-01 | 2024-04-02 | 泉美智能科技(山东)有限公司 | 一种无血清间充质干细胞三维培养基及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101984051A (zh) * | 2010-11-19 | 2011-03-09 | 中山大学 | 适合肿瘤干细胞富集与培养的无血清细胞培养液 |
CN102399742A (zh) * | 2011-09-30 | 2012-04-04 | 东莞中山大学研究院 | 用于哺乳动物唾液腺上皮细胞和唾液腺干细胞培养的无血清培养液 |
CN102719393A (zh) * | 2012-06-05 | 2012-10-10 | 中山大学 | 一种诱导肿瘤干细胞向淋巴管内皮细胞分化的无血清培养基及方法 |
CN102827810A (zh) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | 一种无动物源的脐血干细胞无血清培养基 |
CN102827807A (zh) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | 一种间充质干细胞无血清培养基 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2582788A4 (en) * | 2010-06-17 | 2014-03-19 | Stemrd Inc | SERUM-FREE CHEMICALLY DEFINED CELL CULTURE MEDIUM |
-
2012
- 2012-12-20 CN CN201210557941.6A patent/CN103060264B/zh not_active Expired - Fee Related
-
2013
- 2013-01-31 WO PCT/CN2013/071173 patent/WO2014094386A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101984051A (zh) * | 2010-11-19 | 2011-03-09 | 中山大学 | 适合肿瘤干细胞富集与培养的无血清细胞培养液 |
CN102399742A (zh) * | 2011-09-30 | 2012-04-04 | 东莞中山大学研究院 | 用于哺乳动物唾液腺上皮细胞和唾液腺干细胞培养的无血清培养液 |
CN102719393A (zh) * | 2012-06-05 | 2012-10-10 | 中山大学 | 一种诱导肿瘤干细胞向淋巴管内皮细胞分化的无血清培养基及方法 |
CN102827810A (zh) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | 一种无动物源的脐血干细胞无血清培养基 |
CN102827807A (zh) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | 一种间充质干细胞无血清培养基 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111040945A (zh) * | 2019-12-30 | 2020-04-21 | 安徽惠恩生物科技股份有限公司 | 一种多种类干细胞培养皿及其培养基 |
CN113215095A (zh) * | 2021-05-26 | 2021-08-06 | 生物岛实验室 | 组合物、培养基补充剂以及干细胞培养基及培养方法 |
CN113215095B (zh) * | 2021-05-26 | 2023-03-31 | 生物岛实验室 | 组合物、培养基补充剂以及干细胞培养基及培养方法 |
WO2023016510A1 (zh) * | 2021-08-13 | 2023-02-16 | 无锡赛比曼生物科技有限公司 | 一种用于低温保存脂肪间充质干细胞的保存液 |
WO2023065384A1 (zh) * | 2021-10-22 | 2023-04-27 | 中国医学科学院生物医学工程研究所 | 一种人间充质干细胞培养基 |
CN114807028A (zh) * | 2022-06-02 | 2022-07-29 | 广州美健生物技术有限公司 | 一种无血清间充质干细胞培养基及干细胞培养方法 |
CN114807028B (zh) * | 2022-06-02 | 2022-11-01 | 深圳格泰赛尔生物科技有限公司 | 一种无血清间充质干细胞培养基及干细胞培养方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103060264B (zh) | 2015-01-21 |
CN103060264A (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014094386A1 (zh) | 一种干细胞培养基及其应用和干细胞培养方法 | |
US9321995B2 (en) | Stem cell culture medium and its applications as well as a stem cell culture method | |
JP6148429B2 (ja) | ヒト多能性幹細胞の培養方法 | |
US7932084B2 (en) | Methods and compositions for growing adipose stem cells | |
JP2019141074A (ja) | 軟骨細胞系統細胞及び/又は軟骨様組織を作製するための方法及び組成物 | |
JP7196216B2 (ja) | 改善された幹細胞組成物 | |
JP7410899B2 (ja) | 間葉系幹細胞の細胞培養法 | |
CN103243070B (zh) | 一种干细胞培养基及其应用 | |
WO2010140698A1 (ja) | 多能性幹細胞からの神経堤細胞群の分化誘導方法 | |
US20090170200A1 (en) | Stem cell medium | |
JPWO2012056997A1 (ja) | 多能性幹細胞の分化誘導効率を改善するための方法及び培地 | |
KR20060076781A (ko) | 세포 배양 배지 | |
WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
US20160340652A1 (en) | Culture medium for stem cell differentiation | |
US11712451B2 (en) | Agent for promoting wound healing comprising platelet-like cell co-expressing platelet surface antigen and mesenchymal cell surface antigen | |
US20230002729A1 (en) | Cell culture medium composition | |
RU2640556C2 (ru) | Культуральная среда для мезенхимальных стволовых клеток человека | |
JP2016073323A (ja) | ヒト多能性幹細胞の培養方法 | |
RU2631005C1 (ru) | Способ культивирования клеток слюнной железы человека | |
CN116751735B (zh) | 一种脐带间充质干细胞的无血清培养方法 | |
WO2023065384A1 (zh) | 一种人间充质干细胞培养基 | |
WO2023125753A1 (en) | Compositions and methods for culturing stem cells | |
CA3022549C (en) | Culture media for multipotent stem cells | |
Phruksaniyom et al. | Effect of Culture Conditions on Colony-Forming Ability of Stem Cells from Human Exfoliated Deciduous Teeth. | |
CN112300985A (zh) | 一种快速提升哺乳类动物骨髓间充质干细胞增殖效率的增殖培养基及增殖培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 13885000 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13865048 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13865048 Country of ref document: EP Kind code of ref document: A1 |